5539766

Involucrin Antibody (IVRN/827), Novus Biologicals™

Mouse Monoclonal Antibody

Manufacturer: Fischer Scientific

The price for this product is unavailable. Please request a quote

Antigen

Involucrin

Concentration

0.2mg/mL

Applications

Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

Conjugate

Unconjugated

Host Species

Mouse

Research Discipline

Extracellular Matrix

Formulation

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

Gene ID (Entrez)

3713

Immunogen

Purified involucrin from human keratinocytes

Primary or Secondary

Primary

Content And Storage

Store at 4C.

Clone

IVRN/827

Dilution

Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.1 - 0.2 ug/ml, Immunofluorescence 1 - 2 ug/ml

Classification

Monoclonal

Form

Purified

Regulatory Status

RUO

Target Species

Human

Gene Alias

involucrin

Gene Symbols

IVL

Isotype

IgG1 κ

Purification Method

Protein A or G purified

Test Specificity

It recognizes a protein of 66kDa-170kDa, identified as involucrin. In Western blotting of cultured human keratinocytes, this MAb reacts with a 120kDa protein. Involucrin is expressed in a range of stratified squamous epithelia, including the cornea, which lacks a distinct cornified layer. In normal epidermis, it is first expressed in the upper spinous layers, and in keratinocyte cultures, all cells that have left the basal layer express it. Involucrin expression is altered in pathological conditions: in psoriasis and other benign epidermal hyperplasias, involucrin expression begins closer to the basal layer than normal; expression is abnormal in squamous cell carcinomas and premalignant lesions, and is reduced in severe dysplasias of the larynx and cervix.

Related Products

Img

Fischer Scientific

5540589

Mouse Monoclonal Antibody...

Img

Fischer Scientific

5540589

Mouse Monoclonal Antibody...

Img

Fischer Scientific

5539572

Mouse Monoclonal Antibody has been ...

Img

Fischer Scientific

5539737

Mouse Monoclonal Antibody...

Img

Fischer Scientific

5539736

Mouse Monoclonal Antibody...

Img

Fischer Scientific

5539736

Mouse Monoclonal Antibody...

Img

Fischer Scientific

5539569

Mouse Monoclonal Antibody...

Img

Fischer Scientific

5540439

Mouse Monoclonal Antibody...

Description

  • Ensure accurate, reproducible results in Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence Involucrin Monoclonal specifically detects Involucrin in Human samples
  • It is validated for Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunofluorescence.

Compare Similar Items

Show Difference

Img

Fischer Scientific

5539766

Mouse Monoclonal Antibody...


Antigen:
Involucrin

Concentration:
0.2mg/mL

Applications:
Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

Conjugate:
Unconjugated

Host Species:
Mouse

Research Discipline:
Extracellular Matrix

Formulation:
10mM PBS and 0.05% BSA with 0.05% Sodium Azide

Gene ID (Entrez):
3713

Immunogen:
Purified involucrin from human keratinocytes

Primary or Secondary:
Primary

Content And Storage:
Store at 4C.

Clone:
IVRN/827

Dilution:
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.1 - 0.2 ug/ml, Immunofluorescence 1 - 2 ug/ml

Classification:
Monoclonal

Form:
Purified

Regulatory Status:
RUO

Target Species:
Human

Gene Alias:
involucrin

Gene Symbols:
IVL

Isotype:
IgG1 κ

Purification Method:
Protein A or G purified

Test Specificity:
It recognizes a protein of 66kDa-170kDa, identified as involucrin. In Western blotting of cultured human keratinocytes, this MAb reacts with a 120kDa protein. Involucrin is expressed in a range of stratified squamous epithelia, including the cornea, which lacks a distinct cornified layer. In normal epidermis, it is first expressed in the upper spinous layers, and in keratinocyte cultures, all cells that have left the basal layer express it. Involucrin expression is altered in pathological conditions: in psoriasis and other benign epidermal hyperplasias, involucrin expression begins closer to the basal layer than normal; expression is abnormal in squamous cell carcinomas and premalignant lesions, and is reduced in severe dysplasias of the larynx and cervix.

Img

Fischer Scientific

5539779

Mouse Monoclonal Antibody...


Antigen:
Isocitrate Dehydrogenase 1/IDH1

Concentration:
0.2mg/mL

Applications:
Western Blot, Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

Conjugate:
Unconjugated

Host Species:
Mouse

Research Discipline:
Stem Cell Markers

Formulation:
1.0mM PBS and 0.05% BSA with 0.05% Sodium Azide

Gene ID (Entrez):
3417

Immunogen:
Recombinant fragment (119 Amino acid residues around aa 280-420) of human IDH1 protein

Primary or Secondary:
Primary

Content And Storage:
Store at 4C.

Clone:
IDH1/1152

Dilution:
Western Blot 0.5 - 1.0 ug/ml, Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml

Classification:
Monoclonal

Form:
Purified

Regulatory Status:
RUO

Target Species:
Human

Gene Alias:
Cytosolic NADP-isocitrate dehydrogenase, EC 1.1.1.42, IDCD, IDH, IDP, IDPC, isocitrate dehydrogenase [NADP] cytoplasmic, isocitrate dehydrogenase 1 (NADP+), soluble, NADP(+)-specific ICDH, NADP-dependent isocitrate dehydrogenase, cytosolic, NADP-dependent isocitrate dehydrogenase, peroxisomal, Oxalosuccinate decarboxylase, PICD

Gene Symbols:
IDH1

Isotype:
IgG1 κ

Purification Method:
Protein A or G purified

Test Specificity:
It recognizes a 45kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH1 catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming ketoglutarate and CO2 in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of ketoglutarate. During this process, either NADH or NADPH is produced along with CO2. Recently, an inactivating mutation of IDH1 has been implicated in glioblastoma. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.

Img

Fischer Scientific

5539779

Mouse Monoclonal Antibody...


Antigen:
Isocitrate Dehydrogenase 1/IDH1

Concentration:
0.2mg/mL

Applications:
Western Blot, Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

Conjugate:
Unconjugated

Host Species:
Mouse

Research Discipline:
Stem Cell Markers

Formulation:
1.0mM PBS and 0.05% BSA with 0.05% Sodium Azide

Gene ID (Entrez):
3417

Immunogen:
Recombinant fragment (119 Amino acid residues around aa 280-420) of human IDH1 protein

Primary or Secondary:
Primary

Content And Storage:
Store at 4C.

Clone:
IDH1/1152

Dilution:
Western Blot 0.5 - 1.0 ug/ml, Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml

Classification:
Monoclonal

Form:
Purified

Regulatory Status:
RUO

Target Species:
Human

Gene Alias:
Cytosolic NADP-isocitrate dehydrogenase, EC 1.1.1.42, IDCD, IDH, IDP, IDPC, isocitrate dehydrogenase [NADP] cytoplasmic, isocitrate dehydrogenase 1 (NADP+), soluble, NADP(+)-specific ICDH, NADP-dependent isocitrate dehydrogenase, cytosolic, NADP-dependent isocitrate dehydrogenase, peroxisomal, Oxalosuccinate decarboxylase, PICD

Gene Symbols:
IDH1

Isotype:
IgG1 κ

Purification Method:
Protein A or G purified

Test Specificity:
It recognizes a 45kDa protein, which is identified as isocitrate dehydrogenase (IDH1). It belongs to the isocitrate and isopropylmalate dehydrogenases family. IDH1 catalyzes the third step of the citric acid cycle, which involves the oxidative decarboxylation of isocitrate, forming ketoglutarate and CO2 in a two-step reaction. The first step involves the oxidation of isocitrate to the intermediate oxalosuccinate, while the second step involves the production of ketoglutarate. During this process, either NADH or NADPH is produced along with CO2. Recently, an inactivating mutation of IDH1 has been implicated in glioblastoma. IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.

Img

Fischer Scientific

5539789

Mouse Monoclonal Antibody...


Antigen:
Kallikrein 3/PSA

Concentration:
0.2mg/mL

Applications:
Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

Conjugate:
Unconjugated

Host Species:
Mouse

Research Discipline:
Cancer, Cellular Markers, Prostate Cancer, Tumor Biomarkers

Formulation:
10mM PBS and 0.05% BSA with 0.05% Sodium Azide

Gene ID (Entrez):
354

Immunogen:
PSA (p30) from human sperm plasma

Primary or Secondary:
Primary

Content And Storage:
Store at 4C.

Clone:
A67-B/E3 + 1A7

Dilution:
Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 0.5 - 1.0 ug/ml

Classification:
Monoclonal

Form:
Purified

Regulatory Status:
RUO

Target Species:
Human

Gene Alias:
APS seminin, EC 3.4.21, EC 3.4.21.77, Gamma-seminoprotein, hK3, kallikrein 3, (prostate specific antigen), Kallikrein-3, kallikrein-related peptidase 3, KLK2A1, P-30 antigen, prostate specific antigen, prostate-specific antigen, PSA, PSA semenogelase, Semenogelase, Seminin

Gene Symbols:
KLK3

Isotype:
IgG

Purification Method:
Protein A or G purified

Test Specificity:
Recognizes a single protein of 33-34kDa, identified as the prostate specific antigen (PSA). This MAb is highly specific to PSA and stains prostatic secretory and ductal epithelium in both normal and neoplastic tissues. PSA is a chymotrypsin-like serine protease (kallikrein family) exclusively produced by the prostate epithelium, and abundant in seminal fluid. PSA can be detected in the sera of patients with prostatic carcinoma. It is predominantly complexed to a liver-derived serine protease inhibitor, alpha-1-antichymotrypsin (ACT). A higher proportion of serum PSA is complexed to ACT in prostate cancer than in benign prostate hyperplasia.